This study is designed as a Phase-I, 2-period, cross-over, randomised, open-label, single
centre study to determine bioequivalence of a single 32 mg dose of the proposed commercial
oral suspension of candesartan cilexetil (1 mg/mL) and a single 32 mg dose of the candesartan
cilexetil oral suspension (1.6 mg/mL) used in the paediatric program.